Cerus Corporation (NASDAQ:CERS), better known for offering world-class biomedical products, announced that U.S. Food And Drug Administration had approved its INTERCEPT Blood System. Now that the company has received FDA approval, it can use this system in the treatment procedure of platelets suspended in 100% plasma.
Insights of Matter
It’s not the first time when Cerus has received a positive response from FDA. As per the reports, U.S. Food And Drug Administration first approved the INTERCEPT Blood System two years back in 2014 for the treatment of those platelets that were collected in InterSol, a commercial platelet additive solution. InterSol may sound new to U.S. market, but it has been in use in Europe for quite some time.
Now when the awareness about InterSol is gaining momentum, FDA has approved these addictive solutions. They are slowly being introduced into hospital operation system and blood centers.
The senior management team of the company is delighted to announce this update and hopes that it will receive positive feedback in U.S. market similar to the European market. According to William ‘Obi’ Greenman, CEO & President, Cerus, the recent approval from FDA shows company’s progress towards the compatibility of optimal collection platform. Cerus received excellent feedback in Europe for many years and now hopes for the similar response in the U.S. market as well.
Greenman further added that many of Cerus’ patients in U.S. had been waiting for this approval for a very long time so that they could begin implementing INTERCEPT platelets. Going forward, Cerus will look forward to collaborating with different centers to make INTERCEPT platelets available all across the country without any hassle.
It has plans ready for the next phase of promotion and commercialization of INTERCEPT Blood System available with it; however, the details of all the proposed initiatives will be announced from time to time to get the best possible results.
